Potential effects of liver dysfunction at the time of diagnosis in patients with acute myeloid leukemia

Fatma Yilmaz1, Derya Insal Saygili2, Bugra Saglam3

  • 1Department of Hematology, Etlik City Hospital, Ankara 06170, Turkey.

Insights

Liver dysfunction in acute myeloid leukemia (AML) patients at diagnosis is linked to higher infection rates and poorer outcomes. Early liver function tests are crucial for assessing AML prognosis and guiding treatment strategies.

Area of Science:

  • Hematology
  • Oncology
  • Hepatology

Background:

  • Mild aminotransferase elevations are common in acute myeloid leukemia (AML) patients at diagnosis.
  • Liver dysfunction at diagnosis can be a prognostic indicator in AML.
  • Investigating liver dysfunction aids in predicting patient outcomes.

Purpose of the Study:

  • To investigate liver dysfunction at the time of AML diagnosis.
  • To identify parameters associated with liver dysfunction in AML patients.
  • To determine the prognostic significance of liver dysfunction in AML.

Main Methods:

  • Retrospective study of 90 AML patients.
  • Analysis of demographic data, hemogram, anemia parameters, MRD, risk category, hepatosplenomegaly, infection, NRT, and PRT.
  • Statistical analysis including Mann Whitney U-test, Chi-squared test, logistic regression, and ROC curve analysis.

Main Results:

  • Patients with liver dysfunction showed significantly higher NRT, PRT, MRD positivity, infection rates, and belonged to higher-risk categories.
  • Liver dysfunction was associated with increased infection, poorer prognosis, and mortality.
  • Liver function tests are simple, rapid, and necessary during initial AML evaluation.

Conclusions:

  • Liver dysfunction at AML diagnosis is a significant indicator of poor prognosis.
  • Early identification of liver dysfunction aids in risk stratification and management of AML patients.
  • Liver function tests should be routinely included in the initial assessment of AML patients.

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
844
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
277
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
62